Advertisement

Journal of Neuro-Oncology

, Volume 93, Issue 3, pp 437–438 | Cite as

Can cetuximab affect paraneoplastic myopathy?

  • Eleni Galani
  • Anastasios BonakisEmail author
  • Christos Christodoulou
  • George Klouvas
  • Drougou Angeliki
  • Dimostenis Skarlos
Case Report

Abstract

Cetuximab given concurrently with chemotherapy has shown survival benefit for patients with metastatic colon cancer. We report a case of a patient with metastatic colon cancer who developed paraneoplastic necrotizing myopathy that possibly responded to cetuximab despite lack of improvement of the underlying cancer.

Keywords

Paraneoplastic myopathy Cetuximab Epidermal growth factor 

References

  1. 1.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345. doi: 10.1056/NEJMoa033025 PubMedCrossRefGoogle Scholar
  2. 2.
    Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A (1998) Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50(3):764–767PubMedGoogle Scholar
  3. 3.
    Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM (2007) Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 17(5):404–408. doi: 10.1016/j.nmd.2007.01.004 PubMedCrossRefGoogle Scholar
  4. 4.
    Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24:487–499. doi: 10.1007/s10555-005-6192-2 PubMedCrossRefGoogle Scholar
  5. 5.
    Kim J, Lee CK, Park HJ, Kim HJ, So HH, Lee KS, Lee HM, Roh HY, Choi WS, Park TK, Kim B (2006) Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J Pharmacol Sci 101(2):135–143. doi: 10.1254/jphs.FP0060021 PubMedCrossRefGoogle Scholar
  6. 6.
    Florian JA, Watts SW (1999) Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 276(3 Pt 2):H976–H983PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Eleni Galani
    • 1
  • Anastasios Bonakis
    • 2
    Email author
  • Christos Christodoulou
    • 1
  • George Klouvas
    • 1
  • Drougou Angeliki
    • 3
  • Dimostenis Skarlos
    • 1
  1. 1.Second Oncology DepartmentMetropolitan HospitalAthensGreece
  2. 2.Egenition Hospital, Neurological DepartmentUniversity of AthensAthensGreece
  3. 3.Department of HistopathologyRed Cross HospitalAthensGreece

Personalised recommendations